Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PARETEUM CorpTEUM · Entity 144276 | Director | February 19, 2017 | February 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PARETEUM Corp
Report date February 19, 2017 · Filed February 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 451,949 |
Reported balance
After 2017-02-19 transaction · row 1
1 source rowRow 1 · 2017-02-19 · Purchase · Acquired 275,911 · Balance 451,949 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 567,186 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 225,670 · Balance 567,186 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 804,646 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 237,460 · Balance 804,646 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 439,774 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 364,872 · Balance 439,774 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 826,454 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 826,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418321 · ownership.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 364,872 | $38.61 | $14,087,707.92 |
DisclosureSEC source: 0001193125-26-418321 · ownership.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 439,774 F4 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 237,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418321 · ownership.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 804,646 F3 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 225,670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418321 · ownership.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 567,186 F2 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 21:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 2,775 | $36.69 | $101,814.75 |
DisclosureSEC source: 0001628280-26-063076 · wk-form4_1790111498.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,196 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 2,775 | $26.04 | $72,261.00 |
DisclosureSEC source: 0001628280-26-044696 · wk-form4_1782161414.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 730,971 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 21:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 11,101 | $19.12 | $212,251.12 |
DisclosureSEC source: 0001628280-26-020581 · wk-form4_1774300146.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 733,746 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 86,186 | $22.65 | $1,952,112.90 |
DisclosureSEC source: 0001628280-26-012474 · wk-form4_1772146538.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744,847 F5 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the performance-based restricted stock award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 219,024 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012474 · wk-form4_1772146538.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 831,033 F4 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the number of shares granted based on specific performance metrics of the registrant during the period beginning on January 1, 2024 through December 31, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 67,010 | $22.65 | $1,517,776.50 |
DisclosureSEC source: 0001628280-26-012474 · wk-form4_1772146538.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 612,009 F3 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 170,291 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012474 · wk-form4_1772146538.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,019 F2 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 118,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012474 · wk-form4_1772146538.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508,728 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 22:18 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 31,165 | $25.33 | $789,409.45 |
DisclosureSEC source: 0001628280-25-052129 · wk-form4_1763072290.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,998 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.05 to $25.87, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 22:18 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 33,418 | $25.88 | $864,857.84 |
DisclosureSEC source: 0001628280-25-052129 · wk-form4_1763072290.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,163 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.64 to $26.40, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:18 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 35,417 | $26.15 | $926,154.55 |
DisclosureSEC source: 0001628280-25-052129 · wk-form4_1763072290.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,581 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.85 to $26.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 21:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 37,795 | $27.30 | $1,031,803.50 |
DisclosureSEC source: 0001628280-25-046297 · wk-form4_1761339822.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 489,998 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 10-19-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 112,835 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014179 · wk-form4_1742512041.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,793 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation. Read SEC document |
| October 31, 2024 Filed Jan 9, 2025 00:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 46,896 | $23.43 | $1,098,773.28 |
DisclosureSEC source: 0001628280-25-000984 · wk-form4_1736381439.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 414,958 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 10-19-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,249 | $16.60 | $120,333.40 |
DisclosureSEC source: 0001628280-24-010745 · wk-form4_1710294220.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,854 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 29,206 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010745 · wk-form4_1710294220.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 469,103 F1 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 22:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,642 | $16.76 | $44,279.92 |
DisclosureSEC source: 0001628280-24-001982 · wk-form4_1706048990.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,897 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-04-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 19, 2023 Filed Nov 1, 2023 21:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 394,856 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-036052 · wk-form4_1698874183.xml · derivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,856 Underlying: Common Stock · 394,856 shares Expires not disclosed F3 · shares: The restricted stock was granted pursuant to the Executive Employment Agreement. The restricted stock will vest in equal annual installments so long as the reporting owner remains employed by the registrant through January 1, 2027. F3 · derivative.exercise_date: The restricted stock was granted pursuant to the Executive Employment Agreement. The restricted stock will vest in equal annual installments so long as the reporting owner remains employed by the registrant through January 1, 2027. F3 · derivative.expiration_date: The restricted stock was granted pursuant to the Executive Employment Agreement. The restricted stock will vest in equal annual installments so long as the reporting owner remains employed by the registrant through January 1, 2027. Read SEC document |
| October 19, 2023 Filed Nov 1, 2023 21:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 394,856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-036052 · wk-form4_1698874183.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,539 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of their employment agreement. F2 · balance_after: This reflects the total amount beneficially owned by the reporting person as of October 19, 2023. Previous Form 4's filed by the reporting person before October 19, 2023 did not reflect the acquisition of 2,421 shares. Read SEC document |
| October 01, 2023 Filed Oct 10, 2023 21:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-034205 · wk-form4_1696973193.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,262 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant. Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:49 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionRestricted Stock Award · Derivative | 4,740 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-014865 · rdgdoc.xml · derivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,740 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · derivative.expiration_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:49 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 4,740 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-014865 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| January 19, 2023 Filed Jan 21, 2023 00:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,801 | $23.19 | $88,145.19 |
DisclosureSEC source: 0001437749-23-001486 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,160 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 19, 2023 Filed Jan 25, 2023 00:00 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,801 | $23.19 | $88,145.19 |
DisclosureSEC source: 0001437749-23-001698 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,160 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 04, 2023 Filed Jan 19, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 9,647 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-001269 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,961 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 33,905 | $20.59 | $698,103.95 |
DisclosureSEC source: 0001437749-22-028232 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,314 F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.83, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,500 | $20.20 | $30,300.00 |
DisclosureSEC source: 0001437749-22-028232 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,219 F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.13 to $20.25, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 28, 2022 Filed Dec 1, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,400 | $21.44 | $115,776.00 |
DisclosureSEC source: 0001437749-22-028232 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,719 F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.64, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 28, 2022 Filed Dec 1, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,600 | $20.75 | $95,450.00 |
DisclosureSEC source: 0001437749-22-028232 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,119 F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.29 to $21.29, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 23, 2022 Filed Nov 24, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,500 | $21.71 | $97,695.00 |
DisclosureSEC source: 0001437749-22-028058 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,719 F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.52 to $21.88, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 21, 2022 Filed Nov 24, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,500 | $21.63 | $205,485.00 |
DisclosureSEC source: 0001437749-22-028058 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,219 F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $21.81, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2022 Filed Nov 19, 2022 01:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,500 | $22.13 | $33,195.00 |
DisclosureSEC source: 0001437749-22-027791 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,719 F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.08 to $22.22, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 01:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,500 | $23.21 | $34,815.00 |
DisclosureSEC source: 0001437749-22-027791 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,219 F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.15 to $23.29, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,000 | $24.53 | $147,180.00 |
DisclosureSEC source: 0001437749-22-027484 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,719 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.15 to $24.94, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 14,000 | $23.57 | $329,980.00 |
DisclosureSEC source: 0001437749-22-027484 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,719 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.09 to $24.07, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 00:12 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 8,552 | $22.69 | $194,044.88 |
DisclosureSEC source: 0001437749-22-023981 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,719 F1 · kind: The sales reported herein were made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 00:13 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,233 | $21.95 | $27,064.35 |
DisclosureSEC source: 0001437749-22-023627 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,271 F1 · kind: The sales reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.94 to $21.97, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 14, 2022 Filed Aug 17, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 535 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-020754 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,504 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| July 29, 2022 Filed Aug 3, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-018510 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,969 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| July 17, 2022 Filed Jul 20, 2022 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 828 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-017386 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,286 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| July 12, 2022 Filed Jul 15, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,158 | $15.79 | $144,604.82 |
DisclosureSEC source: 0001437749-22-017163 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,458 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 03, 2022 Filed Jul 7, 2022 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-016771 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,616 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| June 19, 2022 Filed Jun 22, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 955 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-015530 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,716 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| June 05, 2022 Filed Jun 8, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-014541 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,761 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| May 22, 2022 Filed May 25, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 1,024 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-013462 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,804 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:17 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,530 | $17.59 | $325,942.70 |
DisclosureSEC source: 0001437749-22-009262 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,780 F1 · date: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. F1 · kind: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. F1 · price: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.